ACM
NVCR icon

Accent Capital Management’s NovoCure NVCR Stock Holding History

Accent Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-45
Closed -$801 – 411
2025
Q2 		$801 Hold
45
– – ﹤0.01% 393
2025
Q1 		$802 Sell
45
-51
-53% -$1.16K ﹤0.01% 317
2024
Q4 		$2.86K Hold
96
– – ﹤0.01% 176
2024
Q3 		$1.5K Sell
96
-47
-33% -$852 ﹤0.01% 202
2024
Q2 		$2.45K Buy
143
+25
+21% +$440 ﹤0.01% 168
2024
Q1 		$1.84K Hold
118
– – ﹤0.01% 162
2023
Q4 		$1.76K Buy
+118
New +$1.58K ﹤0.01% 207

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Accent Capital Management's NVCR Position: Q3 2025 in Review

Accent Capital Management sold out of NovoCure (NVCR) in Q3 2025, closing a stake of 45 shares — an estimated $801 sold.

Accent Capital Management first reported a position in NVCR in Q4 2023 and held it in 7 quarters. The position peaked at $2.86K in Q4 2024. 244 funds tracked by Wall St. Rank hold NVCR as of Q3 2025.

  • Accent Capital Management reported no remaining NovoCure position as of Q3 2025 after selling out during the quarter.
  • Accent Capital Management sold 45 NovoCure shares in Q3 2025, an estimated $801.
  • Accent Capital Management first reported a position in NovoCure in Q4 2023 and held it in 7 quarters.
  • Accent Capital Management's NovoCure position peaked at $2.86K in Q4 2024.
  • 244 funds tracked by Wall St. Rank held NovoCure as of Q3 2025.

Based on Accent Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.